United Therapeutics (UTHR) Total Current Liabilities (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Total Current Liabilities data on file, last reported at $599.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 16.96% year-over-year to $599.1 million; the trailing twelve-month figure through Mar 2026 stood at $599.1 million (down 16.96% YoY), and the FY2025 full-year result was $560.6 million, down 24.05% from the prior year.
• Total Current Liabilities advanced to $599.1 million in Q1 2026, from $560.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $873.4 million in Q3 2024 to a low of $292.6 million in Q1 2022.
• A 5-year average of $575.6 million and a median of $560.6 million in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 165.13% in 2024 and slumped 37.45% in 2025, its largest moves.
• Tracing UTHR's Total Current Liabilities over 5 years: stood at $343.2 million in 2022, then surged by 134.38% to $804.4 million in 2023, then declined by 8.24% to $738.1 million in 2024, then decreased by 24.05% to $560.6 million in 2025, then gained by 6.87% to $599.1 million in 2026.
• Business Quant data shows UTHR's Total Current Liabilities at $599.1 million in Q1 2026, $560.6 million in Q4 2025, and $546.3 million in Q3 2025.